HCIT

Healthcare Weekly News and Deals

1. Sword Health to acquire OrangeDot, the parent company of Headspace, in an all-cash transaction reported between $200-$300 million. Sword Health, last valued at about $4 billion after raising just under $500 million, is buying OrangeDot for cash, with OrangeDot surviving as a wholly owned subsidiary. The $200–300 million range is a severe markdown against the roughly $3 billion at which Headspace and Ginger combined in 2021 and sits below the $321 million Headspace had raised. The deal follows Sword’s $285 million purchase of Kaia Health and extends its move from musculoskeletal care into behavioural health alongside its Mind and Dawn products. The Massachusetts filing dates from 22 July; the effective date is 14 September. (Link)
   
2. American Healthcare REIT, Inc. (NYSE: AHR) has completed a $197 million acquisition of two Northern California senior housing communities from a joint venture between Affinius Capital and Alliance Residential Co. American Healthcare REIT has bought Sonrisa Senior Living in Roseville, rebranded Avella at Roseville, and The Watermark at Almaden, 545 units in total, for $197 million. Sonrisa alone traded at $94.1 million. The buyer has now completed roughly $1.4 billion of senior living acquisitions in 2026 and is pursuing a pipeline including $953 million under executed agreements, among them an $873 million Kensington portfolio. Senior housing occupancy reached 89.9% in the second quarter. Note the source headline wrongly casts the REIT as seller. (Link)
   
3. Thomas Park Investments has acquired a four-property, $70 million medical outpatient portfolio from Stewart Investment Properties. The Annapolis healthcare real estate platform paid $70 million for 165,637 square feet across three Mid-Atlantic submarkets. The package is 1420 Beverly Road in McLean, a 47,185-square-foot building fully leased and anchored by MedStar Health; 6849 Old Dominion Drive in McLean, 69,330 square feet and 89% leased with Johns Hopkins Medicine as anchor; Children’s National at the former Takoma Theatre on Fourth Street NW in Washington, 24,140 square feet; and Luminis Health Easton Pavilion in Easton, Maryland, 24,982 square feet and fully leased to Luminis Health. Each asset is health-system anchored with remaining term and contractual rent growth. (Link)
   
4. Ambulatory Partner Holdings has agreed to pay $54 million for a 60% stake in Atlas Surgery Center, the physician-owned neurosurgical ASC in Amherst, New York. Ambulatory Partner Holdings, an LLC owned equally by Rafael Axen, M.D., Matthew Jenkins and Ann Sariego, is buying 60% from seven of the nine physician members who together hold 90%.. Atlas, at 50 George Karl Boulevard, is a multispecialty Article 28 centre known for outpatient neurosurgery, angiograms, carotid stenting and complex spine, running on the order of 3,000 cases a year. Purchase price is equity-funded. New York’s Public Health and Health Planning Council has the establishment application on its 17 September agenda. (Link)
   
5. The Federal Trade Commission has approved the final consent order clearing Ascension Health Alliance’s $3.9 billion acquisition of AmSurg LLC. The FTC finalised its order on 25 August, letting Ascension close a $3.9 billion purchase first agreed in mid-2025. Six centres go to SC Affiliates, a national ASC operator, and a seventh in Panama City to Florida Gastroenterology Center, a physician group already holding a minority stake. The divestitures cover Nashville, Panama City, Tulsa, Waco and Wichita, where the agency alleged reduced competition in gastroenterology, ophthalmology and orthopaedic outpatient procedures. Ascension must also give the FTC prior notice of ASC acquisitions in those metros for ten years. AmSurg operates more than 250 centres across 34 states. (Link)
   
6. McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC from Blackstone (NYSE: BX) for approximately $2.25 billion. McKesson is paying roughly $2.25 billion for the Bethesda-based business after a multi-year Blackstone hold. The buyer is underwriting a services asset rather than a distribution one: biomarker intelligence, laboratory services, a global CRO, market access consulting and commercialisation support. That fits a portfolio McKesson has been reshaping by shedding non-core assets and concentrating capital in oncology and specialty, where Oncology & Multispecialty revenue rose 33% to $14.2 billion in fiscal first quarter 2026. The target will report inside that segment. Closing is subject to customary conditions and regulatory clearances. (Link)
   
7. Eli Lilly and Company (NYSE: LLY) to acquire Merida Biosciences for up to $2.875 billion in cash, adding a precision immunology platform aimed at pathogenic autoantibodies. Consideration is cash up to $2.875 billion, covering an undisclosed upfront payment and contingent milestones. Cambridge-based Merida is building biologics that selectively degrade disease-causing antibodies while sparing normal immune function. Lead program MER511 is in Phase 1 for Graves’ disease and thyroid eye disease, with initial data showing reductions in pathogenic thyroid-stimulating antibodies and a favourable safety profile. A preclinical program, MER769, targets food allergy, asthma and chronic spontaneous urticaria. Merida launched last year with a $121 million Series A co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures. Close is expected in the fourth quarter, subject to customary clearances. (Link)
   
8. Argenx SE (Euronext & Nasdaq: ARGX) completed a $2.2 billion all-cash acquisition of Forte Biosciences, Inc. (Nasdaq: FBRX) at $77.00 per share. The close, announced 27 August, follows a cash tender that drew about 87% of Forte shares. The deal adds FB102, which has clinical proof-of-concept in vitiligo and celiac disease and potential application across multiple autoimmune indications, to argenx’s immunology portfolio. The original agreement was signed 27 July at a 40.5% premium to Forte’s then-close. The transaction extends a 2026 pattern of large-cap immunology buyers paying for de-risked, mechanism-differentiated assets rather than waiting for later-stage readouts. Forte is now a wholly owned subsidiary and will delist from Nasdaq. (Link)
   
9. Advent International has signed a definitive agreement to acquire a majority stake in New Zealand Clinical Research Group in a transaction local press valued at roughly NZ$1 billion, with Waterman Capital and clinician shareholders rolling over. Advent, one of the largest global private equity firms, is buying majority control of NZCR Group, a physician-led clinical trials platform operating across New Zealand and Australia under the NZCR, CMAX, Optimal and Fusion brands. Advent’s own release did not print a price; BusinessDesk and the Australian Financial Review put the equity value at about NZ$1 billion. Waterman Capital, which held 52%, and clinician shareholders are keeping a significant minority. Close is targeted for the fourth quarter subject to regulatory approvals. Advent will partner with CEO Tony Moffatt to deepen sponsor relationships and extend the network internationally. (Link)
   
10. Radiology Partners has signed a definitive agreement to acquire Everlight Radiology from UK private equity firm Livingbridge in a cross-border teleradiology transaction reported at roughly $1 billion (approximately A$1 billion, or about US$715 million). Livingbridge is exiting Everlight after taking majority control in 2021 for a reported US$344 million, having itself bought the asset from Intermediate Capital Group. Everlight’s 800-plus consultant radiologists across 40-plus countries read on a follow-the-sun basis, roughly 2.5 million exams a year for 340-plus clients, avoiding premium US night-shift rates. Radiology Partners intends to extend Mosaic Drafting AI across the acquired network. The 17 August edition covered Livingbridge putting the asset up for sale with Radiology Partners named as bidder; this is the signed agreement. Regulatory clearances pending. (Link)
    
11. TowerBrook Capital Partners to acquire a majority stake in Korean-American women’s wellness brand Rael for 400 billion won ($290 million), buying out a shareholder register including SoftBank Ventures, Unilever Ventures, Lotte Shopping, Shinsegae and GS Retail. TowerBrook is paying 400 billion won, about $290 million, for majority control of Rael, according to people familiar with the matter. The sponsor is buying a consumer health asset with a proven digital channel: Rael became Amazon’s top-selling sanitary pad label on an organic feminine care proposition. The cap table it is taking out is unusually broad for a brand of this size, spanning venture investors SoftBank Ventures and Unilever Ventures alongside strategic Korean retail capital from Lotte Shopping, Shinsegae and GS Retail. The deal is a rare cross-border consumer exit for Korean sponsors in a market skewed toward beauty. (Link)
    
12. BioXcel Therapeutics, Inc. (Nasdaq: BTAI) has filed Chapter 11 and entered a stalking-horse sale with Teva Pharmaceuticals at $57.5 million upfront with milestones up to $125 million. BioXcel and two OnkosXcel subsidiaries petitioned in Delaware on 27 August to run a court-supervised 363 sale of substantially all assets. Teva Pharmaceuticals International GmbH is the stalking-horse bidder for $57.5 million in cash, assumption of specified liabilities, and up to $67.5 million of contingent development payments — a ceiling of $125 million if milestones hit. The estate includes IGALMI, the approved dexmedetomidine sublingual film for agitation, and the pending BXCL501 at-home filing. Teva posted a $5.7 million good-faith deposit and framed the bid as consistent with its Pivot to Growth business-development screen. Higher bids can still emerge at auction. (Link)
    
13. Beyond Air, Inc. (Nasdaq: XAIR) has agreed to sell its controlling stake in NeuroNOS Israel Ltd. to Tel Aviv-listed UNIVO Pharmaceutical Industries (TASE: UNVO) for equity, warrants and up to $32.5 million in milestones. Beyond Air is selling 5,000,000 ordinary shares, about 58% of NeuroNOS on a fully diluted basis. Consideration is UNIVO ordinary shares equal to 19.99% of UNIVO’s issued capital, five-year warrants on a further 19.99% of UNIVO awards exercisable at $0.01, plus up to $6.5 million in cash development milestones and up to $26 million in commercial milestones. NeuroNOS is developing blood-brain-barrier-crossing small molecules that regulate nitric oxide, including BA-102 for autism spectrum disorder and Alzheimer’s and BA-101 for glioblastoma, both still preclinical. The sale lets Beyond Air concentrate on its nitric-oxide device franchise. (Link)
    
14. Savista, the Alpharetta-based healthcare operations and revenue cycle management company, has acquired ABW Medical, an ambulatory revenue cycle management provider serving federally qualified health centres, medical groups, MSOs and virtual care platforms. Savista is buying its way out of a single-segment concentration. Its existing base is acute: more than 800 clients across 49 states, an Epic-certified training workforce and cancer registry services built over 35 years. ABW Medical adds the non-acute end, including community health centres, FQHCs, rural providers and virtual care, plus preferred RCM partner status inside the athenahealth ecosystem. That diversifies EMR exposure away from Epic dependence and adds safety-net billing around Medicaid wraparound payments. Clients pick up Savista’s global delivery scale and eligibility, coding and A/R tooling. (Link)
    
15. Eqwal Group has acquired Atlantic Pro Care, the Portland, Maine prosthetics and orthotics practice, extending the French patient-care network’s East Coast footprint. Eqwal is a global prosthetics and orthotics patient-care group that already owns Steeper in the UK and has been rolling up US clinics including United Prosthetics, American Orthopedics, Optech, South Beach Prosthetics and Prosthetic & Orthotic Group. Atlantic Pro Care, founded in 1993 by J.P. Donovan in Portland, fits custom devices for patients with upper- and lower-limb loss and spinal conditions and handles assessment, fabrication, fitting and rehab. The buyer framed the tuck-in as deepening US patient-care density rather than adding a product brand. No purchase price was published. (Link)
    
16. Thurston Group, the Chicago healthcare-focused private equity firm, has made a platform investment in Pixel Health, a Holyoke, Massachusetts provider of IT consulting and managed services to hospitals and large physician groups. Thurston is entering healthcare IT services for the first time through Pixel Health, founded in 2001 and built into a multi-brand group spanning strategy and transformation consulting, managed IT services, and product sales and licensing. Managing partner Dan Davis framed the deal as consistent with the firm’s practice of backing leaders in high-growth healthcare verticals. The sponsor has installed Brad Mondschein, previously the company’s chief operating and legal officer, as chief executive. The investment case is outsourced IT for health systems that cannot staff internally against rising cybersecurity, interoperability and AI-integration complexity. (Link)
    
17. BV Investment Partners-backed Imagenet has acquired Analytica Consulting, the California data engineering and artificial intelligence firm, in a transaction that closed on 21 August 2026. Imagenet is moving from transaction-processing BPO toward an end-to-end data and AI solutions position for payers. Analytica Consulting, founded in 2015, brings cloud data warehousing, automated ETL pipelines, enterprise visualisation, data science and governance. The commercial angle is in-situ modernisation: layering pipelines and machine learning models on top of health plans’ existing core systems rather than requiring replacement, and applying prescriptive models to denial trends across digital mailroom, claims adjudication and contact centre lines. The target retains its government, life sciences, manufacturing and education clients. (Link)
    
18. Switchboard Health has acquired virtual musculoskeletal provider Livara Health, formerly SpineZone, and closed an oversubscribed equity round of more than $5 million backed by First Trust Capital Partners, Route 66 Ventures, A1 Health Ventures, Allumia Ventures and Martin Ventures. The acquisition converts Switchboard from a referral navigation software layer into a value-based care delivery provider. Livara, founded by orthopaedic spine surgeon Kamshad Raiszadeh, pairs orthopaedic physicians with physical therapists and psychosocial providers, and its outcomes were independently validated by the Validation Institute in 2024 at a 43% reduction in MSK spend, largely through avoided low-value surgery. Switchboard reports routed patient volume up 500% over nine months. This is its second acquisition in under a year after Conduce Health. The raise draws both companies’ existing investors plus new backers. (Link)
    
19. WellStack, the Madison, Wisconsin healthcare data platform led by Chief Executive Rich Waller, has acquired DeLorean Artificial Intelligence, the predictive analytics and risk stratification company led by Chief Executive Severence MacLaughlin, to build an end-to-end healthcare decision intelligence platform.WellStack runs an agentic healthcare data platform with a managed data foundation, analytical studio and modular Decision Hubs. DeLorean AI adds continuous evaluation of clinical, claims and operational data to flag emerging risks, predict adverse events and recommend next actions. The combination targets the gap between data aggregation and intervention, moving customers from what happened to what to do about it. Client case studies cite improved patient adherence, reduced avoidable utilisation and revenue optimisation. MacLaughlin framed the merger as necessary for deep integration with health system data lakes and EMRs. (Link)
    
20. ALIS, the Chicago-based senior living clinical and operational software platform, has acquired the Ella and elbi technology platforms from TapRoot Interventions & Solutions in its first acquisition. ALIS has grown organically from a clinical EHR into an operating system unifying CRM, clinical, billing, AI and business intelligence; Ella and elbi are its first bought capability. The platforms deliver point-of-care, AI-native guidance to frontline caregivers handling dementia and behavioural episodes, using non-pharmacological, person-centred interventions. The economics sit in two measurable outcomes senior living operators are judged on: fewer high-risk behavioural incidents and reduced psychotropic medication reliance, both increasingly tied to reimbursement and length of stay. The platforms also capture behavioural data for population health reporting. Announced at the buyer’s user conference. (Link)
    
21. Globus Medical, Inc. (NYSE: GMED) has acquired Higgs Boson Health, the Durham, North Carolina digital healthcare experience company incubated out of Duke University, to build out its surgical intelligence pillar. What Globus is buying is a team of software developers and AI scientists rather than a revenue base. The acquirer frames the technology as part of a surgical intelligence pillar linking outcomes and analytics in a closed loop across the full episode of care. The stated long-term target is 95% good outcomes at ten years in musculoskeletal surgery, and management is treating patient and provider experience as the missing layer of that ecosystem. The deal follows a second quarter reported on 6 August in which sales grew and non-GAAP EPS guidance was raised. (Link)
    
22. Ekoscan Integrity Group, the Eurazeo-backed French non-destructive testing group, has signed a definitive agreement to acquire the US-based NDT Digital business of Carestream Health, Inc., adding the INDUSTREX computed and digital radiography portfolio. Ekoscan is buying Carestream Health’s US NDT Digital unit — computed radiography systems, digital radiography detectors and imaging software under the INDUSTREX brand — plus the commercial, applications and service organisation in Rochester, New York. Radiographic imaging joins the buyer’s existing ultrasound and eddy-current lines, making a multi-method inspection platform for aerospace and defence, oil and gas and power generation. Carestream is narrowing to healthcare imaging. Ekoscan has been an active consolidator, backed by Eurazeo and EDF Pulse Ventures. Closing is expected in the fourth quarter of 2026. (Link)
    
23. Golden State Dermatology, the physician-owned platform backed by Sorenson Capital and Yukon Partners, has acquired Summit Dermatology in Colorado Springs, its first move outside California. Golden State Dermatology has been a California story, roughly 45 locations and more than 125 providers built through steady practice tuck-ins with Sorenson Capital and Yukon Partners behind it. Summit Dermatology, led by board-certified dermatologists Kevin Whaley and Jeanne Osborn, is the first out-of-state platform entry and opens the Colorado market. The target offers medical and procedural dermatology including skin cancer screening and Mohs micrographic surgery, and retains its location, phone number and staff. Founder Ed Becker frames the strategy as building the leading comprehensive dermatology network across the Western US. (Link)
    
24. Regent Surgical has added Integrated Surgical Center of Arizona, an Avondale multispecialty centre owned by IMS Care, AZ Heart Arrhythmia Associates and Valley GI Consultants, to its ambulatory surgery centre network. Regent Surgical, founded in 2001 and headquartered in Nashville, is a developer and operator of ambulatory surgery centres that has grown from 8 to 32 centres in eight years on site-neutral payment economics. The Arizona addition is a physician-partnership structure rather than an outright buyout: ISCA is owned by IMS Care, the state’s largest independent multispecialty physician group, cardiac electrophysiology group AZ Heart Arrhythmia Associates, and Valley GI Consultants. The strategic value is cardiac migration into outpatient settings across greater Phoenix. Regent also runs a joint venture with Cleveland Clinic. (Link)
    
25. Great Point Partners-backed VetnCare has acquired Geary Veterinary Hospital, the Walnut Creek, California practice founded in 1979 and led by Dr. Gillian Hamilton and Dr. Erica Weiss. Great Point Partners, the Greenwich healthcare-only investor, backed VetnCare in 2022; Geary is the seventh acquisition since, and the second in roughly six weeks after Holistic Veterinary Care in Oakland on 14 July. The company has more than doubled in size in three years under that ownership. The model is regional density rather than national scale: VetnCare concentrates in Northern California, and Geary deepens the East Bay position with a practice offering wellness and preventive care, diagnostics and imaging, surgery, dental and senior pet care. (Link)
    
26. Gravity 360, Inc., the Covington, Kentucky parent of Gravity Diagnostics, has acquired Med-Lake Laboratory, LLC, a CLIA-certified, CAP-accredited high-complexity clinical laboratory in Milledgeville, Georgia. Gravity 360 is building a regional laboratory platform across the southern United States, and Med-Lake gives it an operating base outside Kentucky for the first time. Founded in 2018, the target serves physician practices, skilled nursing facilities, behavioural health providers, judicial programmes and urgent care clinics across Georgia and Alabama, with a testing portfolio spanning clinical toxicology, blood and clinical chemistry, PCR infectious disease and reference services. Rather than consolidating volume into Kentucky, the buyer is retaining the Georgia laboratory, its team and its courier network as the foundation for further expansion. (Link)
    
27. The Landes Group, the Dallas healthcare real estate investment firm, has completed its acquisition of Encore Medical Center in Bryant, Arkansas from Arkansas Heart Hospital and finalised a long-term lease with the University of Arkansas for Medical Sciences, financed with CGA Capital. The Landes Group has closed on a 108,055 square foot, 53-bed hospital and simultaneously locked in its tenant. UAMS gains capacity without deploying capital, paying annual rent reported at roughly $8.16 million with 2.1% escalation and a purchase option in ten years. That structure is the firm’s core strategy: single-tenant, net-leased healthcare assets where ownership is paired with financing that preserves provider capital. Longstanding financing partner CGA Capital supported the transaction, extending a relationship spanning more than $1.2 billion. Arkansas Heart Hospital operates the facility through 30 September, with UAMS assuming control on 1 October. (Link)
    
28. Calera Capital-backed Cypress Health Partners has added Boston Sports Medicine’s ten outpatient clinics to the Bay State Physical Therapy network, effective 27 August. Cypress Health Partners, the Calera Capital-backed outpatient physical therapy platform operating across the Northeast, has partnered with Boston Sports Medicine, one of Greater Boston’s most established physical therapy providers. BSM’s ten outpatient clinics join the Bay State Physical Therapy network, expanding access across Massachusetts communities after more than 25 years of referral-base building. The transaction lands as the outpatient PT sector shifts from pure density plays toward a second phase of value creation focused on patient acquisition and reimbursement yield from existing clinical capacity. (Link)

Venture Deals and Other

1. RA Capital has joined a $120 million Series C for AusperBio Therapeutics that will fund the Phase 3 registrational program for a functional hepatitis B candidate, taking capital raised since 2024 past $340 million.AusperBio, which operates from Hangzhou and California, closed the $120 million Series C on 31 August led by a new strategic investor, with RA Capital Management joining and existing backers HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital and CDH Investments returning. Proceeds fund the Phase 3 registrational program and commercialisation work for lead candidate AHB-137, advance next-generation candidate AHB-171, and support combination-therapy development for chronic hepatitis B. The round is the largest venture check in this week’s book and is a China-plus-US therapeutics financing rather than a services deal. (Link)
   
2. The Gates Foundation has committed up to $35 million to ProFound Therapeutics, including $20 million initially, to find placental and serum protein targets for preeclampsia and eclampsia. ProFound Therapeutics uses its ProFoundry platform against the expanded human proteome. The Gates money funds discovery of novel proteins expressed in placenta and serum from women with preeclampsia and eclampsia, new drug targets and biomarkers, and a disease-specific AI tool. The initial $20 million is committed now; the balance is contingent on program progress. This is foundation capital rather than a priced venture round, and it sits beside rather than inside the company’s existing equity syndicate. Announced 27 August. (Link)
   
3. TJ Parker, general partner at Matrix, has led a $26 million Series A in Metriport, with participation from ARTIS Ventures and Y Combinator, taking the open-source healthcare data infrastructure company to $28.4 million raised. Matrix led the round through TJ Parker, whose stated rationale is channel evidence: he sees dozens of consumer health companies each year and the strongest ones increasingly build on Metriport. The company was founded in 2022 by former AWS engineer Dima Goncharov and Colin Elsinga. The differentiator investors are underwriting is open-source infrastructure against legacy black-box interoperability tools, accessible via a single API, cloud warehouse connection or native EHR application. Customers include Amazon One Medical, Sollis Health and Color Health. Proceeds fund AI chart summarisation and agentic workflows for care teams. (Link)
   
4. Define Ventures has led a $25 million Series B in Arintra, with participation from existing investors Peak XV Partners, Yale New Haven Health Center for Health Care Innovation, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Ten13 and Spider Capital. Define Ventures led the round, taking Arintra’s total funding to $51 million. The investment case rests on measurable throughput: the platform processes more than $5 billion in annual claim value for health systems representing over $50 billion in combined net patient revenue, and reports a 5.1% increase in compliant revenue capture, 32% cost reduction and 43% fewer coding-related denials. Endeavor Health, an early adopter, backed both the Series A and B. Partner Chirag Shah argued no prior solution had been comprehensive enough to move the bottom line. Proceeds fund enterprise expansion and deeper specialty coverage. (Link)
   
5. Wing Venture Capital, Initialized Capital, Sozo Ventures, Hawktail, Lightspeed Venture Partners, Third Kind Venture Capital, Liquid 2 Ventures and SV Angel have backed Outer Bio with roughly $23 million as the Cambridge company exits stealth with its Yuna human-skin platform. What the syndicate is funding is a data asset rather than a clinical one: Yuna keeps full-thickness human skin alive and measurable for four weeks against roughly one week for conventional explants, generating longitudinal multi-omic data that improves the machine learning models over time. The commercial route is consumer skincare first, with partnership revenue already flowing. Founded in 2020 by chief executive Michael Polansky, with Stefani Germanotta on the board. The round size and the syndicate signal investors are underwriting a compounding biological dataset rather than a single product launch. (Link)
   
6. Saga Ventures has led $22.5 million in seed and Series A funding for Hike Medical, joined by Indicator Ventures, Fifth Down Capital, RiverPark Ventures, strategic investor Orthofeet, Inc. and angels including Monaco chief executive Sam Blond and Jerod Mayo. Max Altman of Saga Ventures led the financing, and his stated thesis is vertical integration: owning the entire value chain end to end rather than layering software on a broken industry. The market economics justify it, with roughly $100 billion spent annually on orthotics, prosthetics and durable medical equipment and, per the company’s own research, 60 cents of every dollar lost to waste, remakes and fraud. Operating metrics already show remake rates cut from one in 15 to one in 400. Strategic investor and commercial partner Orthofeet participated. Proceeds fund hiring in San Francisco and manufacturing in Peoria, Illinois. (Link)
   
7. Costanoa has led a $17 million Series A in Onos Health, joined by Flare Capital Partners and strategic investor CVS Health Ventures, the corporate venture arm of CVS Health Corporation (NYSE: CVS). The strategic money matters commercially: Aetna is already a customer, and the company says it is trusted by three of the six largest US health plans. Costanoa partner Amy Cheetham framed behavioural health as one of the largest and least understood categories in healthcare, with wide cost variation and low correlation to quality. Reported outcomes include a 35% improvement in clinical standard adherence and a 6%-plus cut in behavioural health programme costs within twelve months. Proceeds scale the decision-support tools payers use to manage behavioural benefit design and utilisation. (Link)
8. Neotribe Ventures, Listen and Village Global have funded a $12 million round for Boston-based Legato, which has emerged from stealth to commercialise AI hearing-assistance glasses. Neotribe founder and managing director Kittu Kolluri framed the investment as a bet against the industry’s design orthodoxy, arguing that decades spent making hearing aids invisible has suppressed adoption and that positioning assistance as a style choice is the route to the market. The defensible asset is intellectual property: four granted patents and more than 20 pending applications. The competitive set is formidable, including EssilorLuxottica’s Nuance Audio and hearing features from Apple and Samsung. Proceeds fund a launch in the coming months and further development. (Link)
   
9. August Global Partners has led a $10 million convertible note financing for Shape Memory Medical, joined by fellow new investor Taiwania Capital alongside existing backers HBM Healthcare Investments, Earlybird Venture Capital and WexMed II. The convertible structure defers valuation until clinical readouts land. Partner Davian Sim argued clinicians treating aortic aneurysms and dissections have long relied on repurposed materials, and identified an inflection point as two programmes advance. Proceeds fund follow-up in the AAA-SHAPE pivotal trial, fully enrolled at 180 patients across 48 centres, and the FLAGSHIP feasibility study. Both new investors also support Asia-Pacific expansion. HEAL Venture Lab assisted; the note sits ahead of those readouts rather than pricing the company now. (Link)
   
10. Redesign Health has provided $2.25 million in seed funding to OmicsBank, the clinical data infrastructure company founded in 2025 by serial entrepreneurs Sumit Sinha and Vijay Goel.Redesign Health is the sole named backer of this seed round. Head of ventures Neil Patel was explicit about the underwriting order, saying the firm backed the founders first and the market second, citing five companies built between them and the relationship-intensive work of winning hospitals one at a time. The asset being capitalised is a deployed data network: infrastructure inside 90-plus hospitals and laboratories across South Asia, Southeast Asia and the Middle East, covering 12.5 million longitudinal records, 30 million DICOM images, six million pathology slides and 500,000 whole-genome sequences. Proceeds fund US and biopharma expansion. (Link)

CLICK HERE to sign up
for all news and updates